A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know
Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.
Overview
Chief Medical Officer Patrick Harrison Carroll disposed of 10,201 shares of Hims & Hers Health, Inc. (NYSE:HIMS) at $28.15 per share on August 14, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Details
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, demonstrating significant scale within the telehealth and direct-to-consumer healthcare sector. The company's integrated model combines virtual medical consultations with pharmaceutical fulfillment and consumer health products, creating multiple revenue streams and high customer lifetime value. The platform's competitive advantage stems from its seamless user experience, a network of licensed providers, and its ability to deliver comprehensive healthcare solutions through a single digital interface.
Source
Originally published at www.fool.com.